Global Durvalumab Market Growth 2025-2031

December 2025 | 82 pages | ID: G3B06EBC3BDEN
LP Information

Abstracts

The global Durvalumab market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

United States market for Durvalumab is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Durvalumab is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Durvalumab is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Durvalumab players cover Medimmune (AstraZeneca), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Durvalumab Industry Forecast” looks at past sales and reviews total world Durvalumab sales in 2024, providing a comprehensive analysis by region and market sector of projected Durvalumab sales for 2025 through 2031. With Durvalumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Durvalumab industry.

This Insight Report provides a comprehensive analysis of the global Durvalumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Durvalumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Durvalumab market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Durvalumab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Durvalumab.

This report presents a comprehensive overview, market shares, and growth opportunities of Durvalumab market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• 2.4mL Injection
• 10mL Injection

Segmentation by Application:

• Locally Advanced Urothelial Carcinoma
• Metastatic Urothelial Carcinoma
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Medimmune (AstraZeneca)

Key Questions Addressed in this Report

What is the 10-year outlook for the global Durvalumab market?

What factors are driving Durvalumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Durvalumab market opportunities vary by end market size?

How does Durvalumab break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Durvalumab Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Durvalumab by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Durvalumab by Country/Region, 2020, 2024 & 2031
2.2 Durvalumab Segment by Type
  2.2.1 2.4mL Injection
  2.2.2 10mL Injection
2.3 Durvalumab Sales by Type
  2.3.1 Global Durvalumab Sales Market Share by Type (2020-2025)
  2.3.2 Global Durvalumab Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Durvalumab Sale Price by Type (2020-2025)
2.4 Durvalumab Segment by Application
  2.4.1 Locally Advanced Urothelial Carcinoma
  2.4.2 Metastatic Urothelial Carcinoma
  2.4.3 Others
2.5 Durvalumab Sales by Application
  2.5.1 Global Durvalumab Sale Market Share by Application (2020-2025)
  2.5.2 Global Durvalumab Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Durvalumab Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Durvalumab Breakdown Data by Company
  3.1.1 Global Durvalumab Annual Sales by Company (2020-2025)
  3.1.2 Global Durvalumab Sales Market Share by Company (2020-2025)
3.2 Global Durvalumab Annual Revenue by Company (2020-2025)
  3.2.1 Global Durvalumab Revenue by Company (2020-2025)
  3.2.2 Global Durvalumab Revenue Market Share by Company (2020-2025)
3.3 Global Durvalumab Sale Price by Company
3.4 Key Manufacturers Durvalumab Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Durvalumab Product Location Distribution
  3.4.2 Players Durvalumab Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DURVALUMAB BY GEOGRAPHIC REGION

4.1 World Historic Durvalumab Market Size by Geographic Region (2020-2025)
  4.1.1 Global Durvalumab Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Durvalumab Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Durvalumab Market Size by Country/Region (2020-2025)
  4.2.1 Global Durvalumab Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Durvalumab Annual Revenue by Country/Region (2020-2025)
4.3 Americas Durvalumab Sales Growth
4.4 APAC Durvalumab Sales Growth
4.5 Europe Durvalumab Sales Growth
4.6 Middle East & Africa Durvalumab Sales Growth

5 AMERICAS

5.1 Americas Durvalumab Sales by Country
  5.1.1 Americas Durvalumab Sales by Country (2020-2025)
  5.1.2 Americas Durvalumab Revenue by Country (2020-2025)
5.2 Americas Durvalumab Sales by Type (2020-2025)
5.3 Americas Durvalumab Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Durvalumab Sales by Region
  6.1.1 APAC Durvalumab Sales by Region (2020-2025)
  6.1.2 APAC Durvalumab Revenue by Region (2020-2025)
6.2 APAC Durvalumab Sales by Type (2020-2025)
6.3 APAC Durvalumab Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Durvalumab by Country
  7.1.1 Europe Durvalumab Sales by Country (2020-2025)
  7.1.2 Europe Durvalumab Revenue by Country (2020-2025)
7.2 Europe Durvalumab Sales by Type (2020-2025)
7.3 Europe Durvalumab Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Durvalumab by Country
  8.1.1 Middle East & Africa Durvalumab Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Durvalumab Revenue by Country (2020-2025)
8.2 Middle East & Africa Durvalumab Sales by Type (2020-2025)
8.3 Middle East & Africa Durvalumab Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Durvalumab
10.3 Manufacturing Process Analysis of Durvalumab
10.4 Industry Chain Structure of Durvalumab

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Durvalumab Distributors
11.3 Durvalumab Customer

12 WORLD FORECAST REVIEW FOR DURVALUMAB BY GEOGRAPHIC REGION

12.1 Global Durvalumab Market Size Forecast by Region
  12.1.1 Global Durvalumab Forecast by Region (2026-2031)
  12.1.2 Global Durvalumab Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Durvalumab Forecast by Type (2026-2031)
12.7 Global Durvalumab Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Medimmune (AstraZeneca)
  13.1.1 Medimmune (AstraZeneca) Company Information
  13.1.2 Medimmune (AstraZeneca) Durvalumab Product Portfolios and Specifications
  13.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Medimmune (AstraZeneca) Main Business Overview
  13.1.5 Medimmune (AstraZeneca) Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Durvalumab Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Durvalumab Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of 2.4mL Injection
Table 4. Major Players of 10mL Injection
Table 5. Global Durvalumab Sales by Type (2020-2025) & (K Pcs)
Table 6. Global Durvalumab Sales Market Share by Type (2020-2025)
Table 7. Global Durvalumab Revenue by Type (2020-2025) & ($ million)
Table 8. Global Durvalumab Revenue Market Share by Type (2020-2025)
Table 9. Global Durvalumab Sale Price by Type (2020-2025) & (USD/Pcs)
Table 10. Global Durvalumab Sale by Application (2020-2025) & (K Pcs)
Table 11. Global Durvalumab Sale Market Share by Application (2020-2025)
Table 12. Global Durvalumab Revenue by Application (2020-2025) & ($ million)
Table 13. Global Durvalumab Revenue Market Share by Application (2020-2025)
Table 14. Global Durvalumab Sale Price by Application (2020-2025) & (USD/Pcs)
Table 15. Global Durvalumab Sales by Company (2020-2025) & (K Pcs)
Table 16. Global Durvalumab Sales Market Share by Company (2020-2025)
Table 17. Global Durvalumab Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Durvalumab Revenue Market Share by Company (2020-2025)
Table 19. Global Durvalumab Sale Price by Company (2020-2025) & (USD/Pcs)
Table 20. Key Manufacturers Durvalumab Producing Area Distribution and Sales Area
Table 21. Players Durvalumab Products Offered
Table 22. Durvalumab Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Durvalumab Sales by Geographic Region (2020-2025) & (K Pcs)
Table 26. Global Durvalumab Sales Market Share Geographic Region (2020-2025)
Table 27. Global Durvalumab Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Durvalumab Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Durvalumab Sales by Country/Region (2020-2025) & (K Pcs)
Table 30. Global Durvalumab Sales Market Share by Country/Region (2020-2025)
Table 31. Global Durvalumab Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Durvalumab Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Durvalumab Sales by Country (2020-2025) & (K Pcs)
Table 34. Americas Durvalumab Sales Market Share by Country (2020-2025)
Table 35. Americas Durvalumab Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Durvalumab Sales by Type (2020-2025) & (K Pcs)
Table 37. Americas Durvalumab Sales by Application (2020-2025) & (K Pcs)
Table 38. APAC Durvalumab Sales by Region (2020-2025) & (K Pcs)
Table 39. APAC Durvalumab Sales Market Share by Region (2020-2025)
Table 40. APAC Durvalumab Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Durvalumab Sales by Type (2020-2025) & (K Pcs)
Table 42. APAC Durvalumab Sales by Application (2020-2025) & (K Pcs)
Table 43. Europe Durvalumab Sales by Country (2020-2025) & (K Pcs)
Table 44. Europe Durvalumab Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Durvalumab Sales by Type (2020-2025) & (K Pcs)
Table 46. Europe Durvalumab Sales by Application (2020-2025) & (K Pcs)
Table 47. Middle East & Africa Durvalumab Sales by Country (2020-2025) & (K Pcs)
Table 48. Middle East & Africa Durvalumab Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Durvalumab Sales by Type (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Durvalumab Sales by Application (2020-2025) & (K Pcs)
Table 51. Key Market Drivers & Growth Opportunities of Durvalumab
Table 52. Key Market Challenges & Risks of Durvalumab
Table 53. Key Industry Trends of Durvalumab
Table 54. Durvalumab Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Durvalumab Distributors List
Table 57. Durvalumab Customer List
Table 58. Global Durvalumab Sales Forecast by Region (2026-2031) & (K Pcs)
Table 59. Global Durvalumab Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Durvalumab Sales Forecast by Country (2026-2031) & (K Pcs)
Table 61. Americas Durvalumab Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Durvalumab Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. APAC Durvalumab Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Durvalumab Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Europe Durvalumab Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Durvalumab Sales Forecast by Country (2026-2031) & (K Pcs)
Table 67. Middle East & Africa Durvalumab Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Durvalumab Sales Forecast by Type (2026-2031) & (K Pcs)
Table 69. Global Durvalumab Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Durvalumab Sales Forecast by Application (2026-2031) & (K Pcs)
Table 71. Global Durvalumab Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Medimmune (AstraZeneca) Basic Information, Durvalumab Manufacturing Base, Sales Area and Its Competitors
Table 73. Medimmune (AstraZeneca) Durvalumab Product Portfolios and Specifications
Table 74. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 75. Medimmune (AstraZeneca) Main Business
Table 76. Medimmune (AstraZeneca) Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Durvalumab
Figure 2. Durvalumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Durvalumab Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Durvalumab Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Durvalumab Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Durvalumab Sales Market Share by Country/Region (2024)
Figure 10. Durvalumab Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of 2.4mL Injection
Figure 12. Product Picture of 10mL Injection
Figure 13. Global Durvalumab Sales Market Share by Type in 2025
Figure 14. Global Durvalumab Revenue Market Share by Type (2020-2025)
Figure 15. Durvalumab Consumed in Locally Advanced Urothelial Carcinoma
Figure 16. Global Durvalumab Market: Locally Advanced Urothelial Carcinoma (2020-2025) & (K Pcs)
Figure 17. Durvalumab Consumed in Metastatic Urothelial Carcinoma
Figure 18. Global Durvalumab Market: Metastatic Urothelial Carcinoma (2020-2025) & (K Pcs)
Figure 19. Durvalumab Consumed in Others
Figure 20. Global Durvalumab Market: Others (2020-2025) & (K Pcs)
Figure 21. Global Durvalumab Sale Market Share by Application (2024)
Figure 22. Global Durvalumab Revenue Market Share by Application in 2025
Figure 23. Durvalumab Sales by Company in 2025 (K Pcs)
Figure 24. Global Durvalumab Sales Market Share by Company in 2025
Figure 25. Durvalumab Revenue by Company in 2025 ($ millions)
Figure 26. Global Durvalumab Revenue Market Share by Company in 2025
Figure 27. Global Durvalumab Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Durvalumab Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Durvalumab Sales 2020-2025 (K Pcs)
Figure 30. Americas Durvalumab Revenue 2020-2025 ($ millions)
Figure 31. APAC Durvalumab Sales 2020-2025 (K Pcs)
Figure 32. APAC Durvalumab Revenue 2020-2025 ($ millions)
Figure 33. Europe Durvalumab Sales 2020-2025 (K Pcs)
Figure 34. Europe Durvalumab Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Durvalumab Sales 2020-2025 (K Pcs)
Figure 36. Middle East & Africa Durvalumab Revenue 2020-2025 ($ millions)
Figure 37. Americas Durvalumab Sales Market Share by Country in 2025
Figure 38. Americas Durvalumab Revenue Market Share by Country (2020-2025)
Figure 39. Americas Durvalumab Sales Market Share by Type (2020-2025)
Figure 40. Americas Durvalumab Sales Market Share by Application (2020-2025)
Figure 41. United States Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Durvalumab Sales Market Share by Region in 2025
Figure 46. APAC Durvalumab Revenue Market Share by Region (2020-2025)
Figure 47. APAC Durvalumab Sales Market Share by Type (2020-2025)
Figure 48. APAC Durvalumab Sales Market Share by Application (2020-2025)
Figure 49. China Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 53. India Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Durvalumab Sales Market Share by Country in 2025
Figure 57. Europe Durvalumab Revenue Market Share by Country (2020-2025)
Figure 58. Europe Durvalumab Sales Market Share by Type (2020-2025)
Figure 59. Europe Durvalumab Sales Market Share by Application (2020-2025)
Figure 60. Germany Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 61. France Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Durvalumab Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Durvalumab Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Durvalumab Sales Market Share by Application (2020-2025)
Figure 68. Egypt Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Durvalumab Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Durvalumab in 2025
Figure 74. Manufacturing Process Analysis of Durvalumab
Figure 75. Industry Chain Structure of Durvalumab
Figure 76. Channels of Distribution
Figure 77. Global Durvalumab Sales Market Forecast by Region (2026-2031)
Figure 78. Global Durvalumab Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Durvalumab Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Durvalumab Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Durvalumab Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Durvalumab Revenue Market Share Forecast by Application (2026-2031)